SEE MORE BIOLOGY
Our Mission
To revolutionize the diagnostic, prognostic, and predictive treatment of disease by enabling next generation technologies for non-destructively processing and digitally analyzing tissue in 3D.
ClearLight Biotechnologies’ automated instrumentation platform study is featured as the 4th news story in Clinical Lab Products’ Prime email newsletter and on Clinical Lab Products’ magazine.
Imagine
Non-destructive tissue processing and digital spatial image analysis in 3D to facilitate your pre-clinical and clinical research studies
A way to illuminate your tissue microenvironment in a 3D volume
Automating this process and integrating it into your normal tissue processing work flow
ClearLight Biotechnologies and Researchers at the Indiana University’s Melvin and Bren Simon Cancer Center
Announce publication in Scientific Reports-Nature
ClearLight Biotechnologies (formerly ClearLight Diagnostics, LLC) was founded in 2014 by Karl Deisseroth MD, PhD, the inventor of CLARITY, Optogenetics, and STARmap technologies. It is an early stage company focused on developing automated instrumentation and associated reagents to simplify and expedite non-destructive 3D tissue analysis to facilitate preclinical and clinical research applications. The platform will enable an end-to-end solution for 3D analysis of preclinical and clinical models of disease.
Sharla White, PhD presented poster #4690 at AACR Annual Meeting 2019, Atlanta.
Nature posted a video to YouTube describing the CLARITY 3D tissue imaging technology.
4 Major Platform Components
Focus
Could be applied to any application that relies
on 2D thin section FFPE analysis
Applications
Near Term
Research Use Only (RUO) Service Model
and Limited Beta instruments in field
Preclinical/clinical drug development, exploratory technology inclusion in clinical trials
Future
RUO instrument in field, Companion Diagnostics, LDT (ClearLight Biotechnologies has exclusive rights to diagnostic, prognostic, predictive applications)